centration of 6.226 mmol/L with the NIST target concentration based on dry mass, which is 6.304 mmol/L-'calculated with the mean dry mass of 0.8542 g in Table 1 and the certified value of 7.38 mmol/(L g). The result on a dry mass basis, therefore, would have been 1.2% too low in their original work because they did not discuss glucose breakdown at that time. If one took glucose degradation into account, the target would be 6.304 -2.5 x 0.044 = 6.194 mmol/L. In this case the measured value of 6.226 mmol/L would be 0.52% too high.
The authors also state that comparison of values from different laboratories for a SRM are valid only when the same sample vial is used in a split measurement protocol. tients who had undergone neither chemotherapy nor radiation therapy prior to collection of the samples, and who were later diagnosed by pathology as having breast adenocarcinoma. The age distribution at the time of diagnosis was 30-65 years. All the resected tumor specimens were histologically staged based on the TNM dassification (9). The patients examined in this study induded no patients in stages Tis (noninvading tumor), 0, or W, and none was found either macroscopically or histopathologically to have any distant metastases. We also measured immunoreactive bFGF in sera from 23 breast cancer patients one week after the surgical resection of the tumor region of the mammary gland and axillary lymph nodes to assess a possible effect of tumor resection on the concentration of immunoreactive bFGF in their serum.
As shown in Fig. 1 , serum concentrations of bFGF in 25 of 35 (71%) stage I patients with primary breast cancer before surgery were higher than those of normal subjects. Ten of 13(77%) stage H patients and ailS (100%) stage ffl-a patients also showed increased serum immunoreactive bFGF before surgery. On the other hand, only 3 of the 12 (25%) stage I patients who had had surgical In condusion, the results from this study and others support the view that bFGF has an important role in mammary gland tumorigenesis.
The present results demonstrate that the serum concentration of bFGF is increased in most patients with breast carcinoma, even at the early stage, and may be a useful marker for breast cancer.
